Soligenix Inc SNGX

Healthcare Biotechnology

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.

NDAQ:SNGX - Post by User

Soligenix Inc

<< Previous

Bullboard Posts

Next >>

Post by HariboSpeedPeakon Jul 21, 2022 4:59pm

124 Views

Post# 34841651

Benzinga Article on Soligenix

Definitely worth the read if youre thinking about investing in Soligenix or already have. Some great stuff in this article

https://www.benzinga.com/general/biotech/22/07/28139372/soligenix-shares-jump-on-hybrytes-data-from-blood-cancer-study-published-in-medical-journal

<< Previous

Bullboard Posts

Next >>

Regulatory clarity for market evolution: Canada’s position in global crypto industry